Eton Pharmaceuticals Inc (ETON) recently announced its financial results for the quarter ended September 30, 2024, marking the 15th consecutive quarter of sequential product revenue growth. With a continued focus on managing profitability, the company is optimistic that 2025 will be a transformational year.
This commercial-stage company is developing and commercializing pharmaceutical products to address unmet needs in patients suffering from extremely rare conditions. It has 6 commercial products and 3 late-stage pipeline candidates.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com